Journal of Clinical Medicine (Jun 2022)
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
- Anna Waszczuk-Gajda,
- Olaf Penack,
- Giulia Sbianchi,
- Linda Koster,
- Didier Blaise,
- Péter Reményi,
- Nigel Russell,
- Per Ljungman,
- Marek Trneny,
- Jiri Mayer,
- Simona Iacobelli,
- Guido Kobbe,
- Christof Scheid,
- Jane Apperley,
- Cyrille Touzeau,
- Stig Lenhoff,
- Esa Jantunen,
- Achilles Anagnostopoulos,
- Laura Paris,
- Paul Browne,
- Catherine Thieblemont,
- Nicolaas Schaap,
- Jorge Sierra,
- Ibrahim Yakoub-Agha,
- Laurent Garderet,
- Jan Styczynski,
- Helene Schoemans,
- Ivan Moiseev,
- Rafael F. Duarte,
- Zinaida Peric,
- Silvia Montoto,
- Anja van Biezen,
- Malgorzata Mikulska,
- Mahmoud Aljurf,
- Tapani Ruutu,
- Nicolaus Kröger,
- Curly Morris,
- Christian Koenecke,
- Stefan Schoenland,
- Grzegorz W. Basak
Affiliations
- Anna Waszczuk-Gajda
- Department of Hematology, Transplantation and Internal Medicine, University Clinical Centre—The Medical University of Warsaw, 02-097 Warsaw, Poland
- Olaf Penack
- Charité Universitätsmedizin Berlin, 10771 Berlin, Germany
- Giulia Sbianchi
- Tor Vergata University, 00133 Rome, Italy
- Linda Koster
- EBMT Data Office Leiden, 2333 AA Leiden, The Netherlands
- Didier Blaise
- Institut Paoli Calmettes, 13009 Marseille, France
- Péter Reményi
- Dél-Pesti Centrumkórház, 1097 Budapest, Hungary
- Nigel Russell
- Nottingham University, Nottingham NG7 2QL, UK
- Per Ljungman
- Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, 17177 Stockholm, Sweden
- Marek Trneny
- University Hospital, 12808 Prague, Czech Republic
- Jiri Mayer
- University Hospital Brno, 62500 Brno, Czech Republic
- Simona Iacobelli
- Tor Vergata University, 00133 Rome, Italy
- Guido Kobbe
- Heinrich Heine Universitaet, 40225 Duesseldorf, Germany
- Christof Scheid
- University of Cologne, 50923 Cologne, Germany
- Jane Apperley
- Imperial College, London SW7-2BX, UK
- Cyrille Touzeau
- CHU Nantes, 44000 Nantes, France
- Stig Lenhoff
- Skanes University Hospital, 23262 Lund, Sweden
- Esa Jantunen
- Department of Medicine, University of Eastern Finland and Hospital District of North Carelia, Kuopio University Hospital, 70211 Kuopio, Finland
- Achilles Anagnostopoulos
- George Papanicolaou General Hospital, 57010 Thessaloniki, Greece
- Laura Paris
- Division of Hematology, SST Papa Giovanni XXIII, 24127 Bergamo, Italy
- Paul Browne
- Hope Directorate, D08 NHY1 Dublin, Ireland
- Catherine Thieblemont
- Hôpital St. Louis, 75010 Paris, France
- Nicolaas Schaap
- Radboud University Medical Centre, Department of Hematology, 6525 GA Nijmegen, The Netherlands
- Jorge Sierra
- Hospital Santa Creu i Sant Pau, 08001 Barcelona, Spain
- Ibrahim Yakoub-Agha
- CHU de Lille, 59000 Lille, France
- Laurent Garderet
- Centre de Recherche Saint-Antoine, Sorbonne Université-INSERM, UMR_S 938, 75013 Paris, France
- Jan Styczynski
- Department of Pediatric Hematology and Oncology, Collegium Medicum UMK, 85-067 Bydgoszcz, Poland
- Helene Schoemans
- Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium
- Ivan Moiseev
- R.M. Gorbacheva Memorial Institute of Hematology, Oncology and Transplantation, Pavlov University, 197022 Saint-Petersburg, Russia
- Rafael F. Duarte
- Hospital Universitario Puerta de Hierro Majadahonda—Universidad Autónoma de Madrid, 28222 Madrid, Spain
- Zinaida Peric
- Department of Internal Medicine, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
- Silvia Montoto
- Department of Haemato-Oncology, St Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UK
- Anja van Biezen
- EBMT Data Office Leiden, 2333 AA Leiden, The Netherlands
- Malgorzata Mikulska
- Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, 16121 Genoa, Italy
- Mahmoud Aljurf
- Section of Adult Haematolgy/BMT, King Faisal Specialist Hospital & Research Centre Oncology, Riyadh 11564, Saudi Arabia
- Tapani Ruutu
- Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, 00290 Helsinki, Finland
- Nicolaus Kröger
- University Hospital Eppendorf, 20246 Hamburg, Germany
- Curly Morris
- Belfast City Hospital, Belfast BT9 7AB, UK
- Christian Koenecke
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany
- Stefan Schoenland
- Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany
- Grzegorz W. Basak
- Department of Hematology, Transplantation and Internal Medicine, University Clinical Centre—The Medical University of Warsaw, 02-097 Warsaw, Poland
- DOI
- https://doi.org/10.3390/jcm11123541
- Journal volume & issue
-
Vol. 11,
no. 12
p. 3541
Abstract
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.
Keywords
